Enumera Molecular

Enumera Molecular is developing a rapid, low-cost molecular counting platform for clinical diagnostics.


Ann Arbor, MI

CEO: Matthew Cooper
Arboretum Lead: Dan Kidle

May 10, 2022 in Enumera Molecular, Home Page, News Page

Enumera Molecular Acquires Progenity Liquid Biopsy Tech, Raises $12.5M in Series A Round

Progenity said on Thursday that it has divested its collection of discovery-stage biochemical and bioinformatics technologies for rapid, low-cost liquid biopsy testing to newly formed Enumera Molecular.
Read More